Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Monday, May 13, 2024 | Back issues
Courthouse News Service Courthouse News Service

Liver disease drug

NEW YORK — A Manhattan appeals court dismissed a securities fraud class action against French pharmaceutical firm Genfit over its drug to treat liver disease, finding the company disclosed clinical trial results and said its profitability could not be guaranteed.

Click here to read the ruling.    

Categories / Appeals, Briefs, Health, Securities

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...